Novel nasal therapy hopes to reduce the amount of COVID-19 virus reaching the lungs
Another big hitter last month was a piece, first published in September, on a new preventative nasal spray treatment that could reportedly protect people from COVID-19 infection and prevent transmission.
The novel therapy was developed by Australian biotech company, Ena Respiratory, with a study indicating it significantly reduced COVID-19 virus levels in the nose and throat. It also reduced COVID-19 replication by up to 96%, found the research, which was performed by Public Health England (PHE) scientists.
Top five stories from October Fast-tracking COVID-19 vaccine approval Novel nasal therapy hopes to reduce the amount of COVID-19 virus reaching the lungs COVID-19 vaccines - the race to the front Five key takeaways from 10 months of COVID-19 vaccine work Repurposing the BCG vaccine